Tempus AI
A health technology company focused on precision medicine using AI and large-scale genomic and clinical data.
TempusTempus AI, Inc. is a Chicago-based health technology company founded in 2015 by Eric Lefkofsky. The company leverages AI and genomic and clinical data to assist physicians in making data-driven treatment decisions, primarily within oncology, and supports drug discovery and development for pharmaceutical partners.
The company operates across three core business lines: genomics and diagnostics for tumor profiling and hereditary screening, data and services for licensing de-identified clinical and molecular data to biopharma, and AI applications including clinical assistant tools and FDA-regulated algorithmic diagnostics. Notable developments include the FDA 510(k) clearance for Tempus ECG-AF and the acquisition of Ambry Genetics to expand its hereditary screening portfolio.
Publicly listed on the Nasdaq under the ticker TEM as of June 2024, Tempus AI serves a B2B customer base consisting of health systems, providers, and biopharmaceutical companies, positioning it as a key player in the application of AI to clinical and translational medicine.